IBM software growth seen reaccelerating ahead of earnings: Jefferies

Jefferies reiterated a Buy on IBM ahead of the Jan. 28 earnings report, forecasting a reacceleration in software growth driven largely by Red Hat momentum — bookings have accelerated to roughly 20% with OpenShift ARR around $1.8 billion and ~40% bookings growth (including $400M in virtualization bookings and a $700M pipeline). The note highlights HCP delivering its highest bookings quarter and expected ~20% growth, potential upside to the Data & AI portfolio from the CFLT transaction, and a rebound in mainframe transaction-processing revenue as shipped MIPS convert to installed MIPS. Street models cited by Jefferies call for Q4 software growth of 10.2%, infrastructure +10%, consulting +6%, total revenue +9.5% and a 36% free cash flow margin; Jefferies values IBM at $360 PT, comparing 26x CY27 GAAP EPS to peers.

Analysis

Market structure: IBM and its Red Hat stack are the clear winners if bookings convert — OpenShift ARR ~$1.8B, ~40% bookings growth and $700M pipeline imply meaningful upside to software mix and pricing power vs. legacy on‑prem peers. Banks/credit markets should view stronger free cash flow (street FCF margin ~36%) as supportive of credit spreads; expect post‑earnings IV compression in options and a modest equity re‑rating if software becomes ~50% of revenue by 2027.

Risk assessment: Immediate (days) risk is an earnings miss — IBM has marginally missed four straight quarters; short term (weeks–months) risks include slower conversion of shipped MIPS into installed MIPS and uneven Red Hat renewals; long term (quarters–years) tail risks are failed CFLT integration, antitrust/regulatory hurdles or durable competition from AWS/Azure. Hidden deps include channel recognition timing and backlog accounting; key catalysts: Jan 28 Q4 numbers, Red Hat booking cadence and CFLT close.

Trade implications: Primary trade is a sized long in IBM to capture a re‑rating if software execution stabilizes, complemented by a protective options structure to limit downside around Jan 28. Consider a relative value pair vs. Oracle to express a valuation‑recovery view while hedging broad software beta; expect to re‑weight into enterprise software and trim pure cloud infrastructure exposure if IBM proves consistent.

Contrarian angles: Consensus may understate execution risk — the market has priced ~26x CY27 GAAP EPS into IBM (vs ORCL 27x, MSFT 23x) without guaranteed consistency; a beat could be underpriced (multiple expansion), but a single miss could reverse gains sharply. Historical parallels (post‑Red Hat 2019 re‑rate) show re‑ratings are durable only after 2–3 consecutive quarters of consistent beats, so size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in IBM (NYSE:IBM) ahead of Jan 28 earnings (enter within next 3 trading days). Target price $360 within 12–18 months; use an initial stop‑loss at 8% below entry and trim 50% of position at +20%.
• Implement a small pair trade: long IBM 1.5% / short ORCL 1.0% to express relative re‑rating; close if IBM underperforms ORCL by 10% on a 30‑day rolling basis or after 90 days if no upward re‑rating materializes.
• Buy a cost‑limited bullish options spread: March 2026 IBM $300–$340 call spread sized to 0.5–1.0% of portfolio risk (max loss = premium). Rationale: captures post‑earnings re‑rate while limiting IV crush exposure; roll or close if post‑earnings implied vol falls >30%.
• Set hard catalyst rules before scaling: increase IBM size only if (1) Jan 28 software growth ≥ Street 10.2% YoY or management sets FY26 software guide >+10% YoY, (2) Red Hat bookings show sequential acceleration (OpenShift bookings ≥40% YoY or pipeline realization), and (3) CFLT transaction timeline confirmed within 90 days. If any condition fails within 60 days, reduce IBM exposure by 50%.